CIK 0000072444
- Accelerated filer
- Smaller reporting company
Vaxart, Inc.
Sign in to watch- Ticker
- VXRT
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 591212264
- Phone
- +1 650-550-3500
- Business address
- 310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
- Former names
- Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI BIOPHARMACEUTICALS, NABI /DE/, NORTH AMERICAN BIOLOGICALS INC
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Director acquired 2,500 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Director bought 35,000 shares at $2.20 ($76,892)
- 4/A Open-market buy Director bought 70,000 shares at $2.03 ($142,100)
- 4 Open-market buy Director bought 70,000 shares at $1.99 ($139,300)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Director acquired 7,500 shares (grant or award)
- 4 Open-market buy CEO bought 20,000 shares at an average $2.28 ($45,689)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Vice Chairmen acquired 40,000 shares (grant or award)
- 4 Open-market buy EVP, Corporate Dev & Strategy bought 10,000 shares at $2.86 ($28,600)
- 4 Open-market buy EVP, Corporate Dev & Strategy bought 5,000 shares at an average $2.81 ($14,026)
- 4 Open-market buy CEO & President bought 32,031 shares at an average $2.99 ($95,692)
Page 13 of 28 · 550 filings